Abstract:Background: Increasing evidence has indicated that the nuclear receptor subfamily 3 group C member 2 (NR3C2) may be associated with tumorigenesis and patient prognosis for certain types of tumors. However, the clinical significance of NR3C2 is unclear in invasive breast carcinoma (BRCA). Methods: We used bioinformatics to broadly investigate and obtain a deeper understanding of the prognostic significance between NR3C2 and BRCA. RNA-sequencing data and clinical information of patients with BRCA from the Cancer Genome Atlas database were collected for subsequent analysis. The diagnostic efficacy of NR3C2 was evaluated by calculating the receiver operating characteristic curve. The prognostic value of NR3C2 was evaluated by Kaplan-Meier analysis and Cox regression analysis for patients with BRCA. Moreover, the OSbrca database was used to validate NR3C2 as a prognostic biomarker for BRCA. Gene set enrichment analysis (GSEA) and tumor immune infiltration analysis were conducted to explore the molecular mechanism of NR3C2 in BRCA. Results: The expression level of NR3C2 in BRCA tissues decreased compared to that in normal breast tissues (P < 0.001). NR3C2 presented good diagnostic efficacy (AUC = 0.908). Moreover, the expression of NR3C2 was verified using the Oncomine database. High expression of NR3C2 was statistically associated with prolonged overall survival (HR = 0.65, 95% CI: 0.47-0.91, and P = 0.012), progression-free interval (HR = 0.68, 95% CI: 0.49-0.95, and P = 0.024), and disease-specific survival (HR = 0.57, 95% CI: 0.36-0.89, and P = 0.015) for patients with BRCA. Besides, the prognostic value of NR3C2 was verified by the OSbrca database. GSEA results suggested that enriched pathways included neuroactive ligand-receptor interaction, focal adhesion, and ECM-receptor interaction. NR3C2 expression was moderately correlated with mast cells and some T cell subsets in BRCA. Conclusion: NR3C2 is a potential prognostic biomarker that could help clinicians develop more appropriate treatment plans for individual patients with BRCA.

Prognostic biomarker NRG2 correlates with autophagy and epithelial‐mesenchymal transition in breast cancer

Clinical Relevance and Prognostic Value of the Neuronal Protein Neuroligin 2 in Breast Cancer

NR3C2-Related Transcriptome Profile and Clinical Outcome in Invasive Breast Carcinoma

A prognostic biomarker NRG1 promotes U-87 MG glioblastoma cell malignancy by inhibiting autophagy via ERBB2/AKT/mTOR pathway

High NTRK2 protein expression levels may be associated with poorer prognosis of breast cancer patients

Identification and validation of a novel necroptosis-related molecular signature to evaluate prognosis and immune features in breast cancer

High NR2F2 Transcript Level is Associated with Increased Survival and Its Expression Inhibits TGF-β-dependent Epithelial-Mesenchymal Transition in Breast Cancer

Single‑cell RNA‑seq necroptosis‑related genes predict the prognosis of breast cancer and affect the differentiation of CD4+ T cells in tumor immune microenvironment.

LncRNA NBR2 inhibits tumorigenesis by regulating autophagy in hepatocellular carcinoma

GNG2 acts as a tumor suppressor in breast cancer through stimulating MRAS signaling

Low NDRG2 Expression Predicts Poor Prognosis in Solid Tumors

Prognostic analyses of genes associated with anoikis in breast cancer

Effects of the lncRNA NBR2 on the proliferation and autophagy of breast cancer cells under starvation conditions

RRM2 Is a Putative Biomarker and Promotes Bladder Cancer Progression via PI3K/AKT/mTOR Pathway

NRSN2 Promotes Breast Cancer Metastasis by Activating PI3K/AKT/mTOR and NF-κB Signaling Pathways.

Identification of a novel necroptosis-related classifier to predict prognosis and guide immunotherapy in breast invasive carcinoma

A Novel Necroptosis-Associated lncRNA Signature Can Impact the Immune Status and Predict the Outcome of Breast Cancer

NDRG2 expression regulates CD24 and metastatic potential of breast cancer cells.

NRBP2 Functions as a Tumor Suppressor and Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer

Identification of Breast Cancer Subtypes Based on Endoplasmic Reticulum Stress-Related Genes and Analysis of Prognosis and Immune Microenvironment in Breast Cancer Patients

Exploration of Epithelial-Mesenchymal Transition-Related Lncrna Signature and Drug Sensitivity in Breast Cancer